Clinical Trials Logo
  1. Home
  2. Hemoglobinopathies
  3. NCT06107400

Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease

Hemoglobinopathies Clinical Trial

Official title:
Study to Evaluate the Safety and Efficacy of RM-004 Cells for the Treatment of Hemoglobin H-Constant Spring Disease

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of RM-004 for Hemoglobin H-Constant Spring disease.

Clinical Trial Description

This is a non-randomized, one-arm, open label study to evaluate the safety and efficacy of RM-004 for autologous hematopoietic stem cell transplantation (HSCT) for the treatment of Hemoglobin H-Constant Spring disease. Five subjects aged from 12 to 35 years will be recruited in this study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06107400
Study type Interventional
Source The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Contact Xinhua Zhang, MD
Phone +8613321717386
Email zxh303@163.com
Status Recruiting
Phase Early Phase 1
Start date October 8, 2023
Completion date October 31, 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Active, not recruiting NCT03655678 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia Phase 2/Phase 3
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Enrolling by invitation NCT02986698 - In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Phase 1
Completed NCT00744692 - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders Phase 1
Recruiting NCT05799118 - Study of the Role of Genetic Modifiers in Hemoglobinopathies
Active, not recruiting NCT03745287 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Phase 2/Phase 3
Completed NCT00673608 - Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Phase 4
Recruiting NCT04644016 - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Phase 2
Recruiting NCT04853576 - A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) Phase 1/Phase 2
Recruiting NCT05356195 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) Phase 3
Completed NCT03609840 - Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Active, not recruiting NCT01850108 - Non-Myeloablative Conditioning and Bone Marrow Transplantation N/A
Recruiting NCT05329649 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Phase 3
Active, not recruiting NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Completed NCT00153985 - Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies Phase 2
Recruiting NCT03128996 - Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders Phase 1/Phase 2
Completed NCT03149289 - Hepatitis C Virus Infection in Patients With Hemoglobinopathies N/A
Completed NCT00000588 - Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone Phase 2
Not yet recruiting NCT06363760 - A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301